Table 4.

Proportion of women with Low Bone Mass meeting NOF thresholds for treatment (high-risk)^a, and performance characteristics^b of NOF treatment thresholds overall, and based on prior history of fracture

	NOF high-risk; No Fracture	NOF high-risk; Did Fracture	NOF low-risk; No Fracture	NOF low-risk; Did Fracture
	FP, %	TP, %	TN, %	FN, %	Sensitivityc	Specificityd	PPVe	NPVf
Whole Cohort
Hip Fracture	45	4	50	1	0.81	0.53	0.09	0.98
MOF Fracture	39	11	46	5	0.67	0.54	0.22	0.90
No Prior Fracture
Hip Fracture	35	3	61	1	0.74	0.64	0.08	0.98
MOF Fracture	31	7	56	6	0.55	0.65	0.19	0.91
Prior Fracture
Hip Fracture	65	7	27	1	0.88	0.30	0.09	0.97
MOF Fracture	54	18	24	4	0.82	0.31	0.25	0.86

^aNOF high-risk is low bone mass (T score between −1.0 and −2.5 by femoral neck or spine BMD, n=4,464) and 10 year FRAX (including BMD) probability of fracture of ≥3% for hip or ≥20% for major osteoporotic fracture (MOF).⁽⁷⁾

^bFP=false positive; TP=true positive; TN=true negative; FN=false negative. For presentation, we rounded group percentages to whole numbers (thus the group total may not be exactly 100%). PPV=positive predictive value; NPV=negative predictive value.^(14,15)

^cSensitivity, or true positive rate = TP/(TP+FN)

^dSpecificity, or true negative rate = TN/(TN+FP)

^ePPV = TP/(TP+FP)

^fNPV = TN/(TN+FN)